ATE390134T1 - (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen - Google Patents

(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen

Info

Publication number
ATE390134T1
ATE390134T1 AT01939312T AT01939312T ATE390134T1 AT E390134 T1 ATE390134 T1 AT E390134T1 AT 01939312 T AT01939312 T AT 01939312T AT 01939312 T AT01939312 T AT 01939312T AT E390134 T1 ATE390134 T1 AT E390134T1
Authority
AT
Austria
Prior art keywords
piperidinemethanol
dimethoxyphenyl
prodrug
fluorophenyl
alpha
Prior art date
Application number
AT01939312T
Other languages
English (en)
Inventor
Richard Scheyer
Stephen Sorensen
Janice Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE390134T1 publication Critical patent/ATE390134T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
AT01939312T 2000-05-25 2001-05-23 (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen ATE390134T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25

Publications (1)

Publication Number Publication Date
ATE390134T1 true ATE390134T1 (de) 2008-04-15

Family

ID=22768607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939312T ATE390134T1 (de) 2000-05-25 2001-05-23 (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen

Country Status (20)

Country Link
US (3) US20020099076A1 (de)
EP (1) EP1289527B1 (de)
JP (1) JP2003535058A (de)
KR (1) KR100784655B1 (de)
CN (1) CN1436078A (de)
AR (1) AR029666A1 (de)
AT (1) ATE390134T1 (de)
AU (2) AU2001264842B2 (de)
BR (1) BR0111102A (de)
CA (1) CA2410554C (de)
DE (1) DE60133385T2 (de)
DK (1) DK1289527T3 (de)
ES (1) ES2300333T3 (de)
IL (1) IL152908A0 (de)
MX (1) MXPA02011511A (de)
NO (1) NO20025630L (de)
NZ (1) NZ522659A (de)
PT (1) PT1289527E (de)
TW (1) TWI299001B (de)
WO (1) WO2001089498A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281666T3 (es) 2002-07-19 2007-10-01 Biovitrum Ab Novedosos derivados de piperazinil-pirazinona para el tratamiento de los desordenes relacionados con el receptor 5-ht2a.
ES2348467T3 (es) * 2004-09-30 2010-12-07 F. Hoffmann-La Roche Ag Derivados y usos de la benzoxazina y la quinoxalina.
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102006040278A1 (de) * 2006-08-21 2008-03-20 Technische Universität Dresden Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2017172757A1 (en) * 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021428A (en) 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4783471A (en) 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4912117A (en) 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US4877798A (en) 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
EP0325063B1 (de) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit
US5106855A (en) 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
US6004980A (en) 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DK0531410T3 (da) 1990-06-01 1995-01-30 Merrell Dow Pharma (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
AU1118099A (en) * 1997-10-23 1999-05-10 Research Foundation Of The State University Of New York, The Methods of screening potential atypical antipsychotic drugs
KR100682799B1 (ko) * 1998-08-28 2007-02-15 아벤티스 파마슈티칼스 인크. Ｒ(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 수면 장애 치료용 약제학적 조성물
EE200100219A (et) * 1998-10-14 2002-08-15 Aventis Pharmaceuticals Inc. (+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli estrid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same

Also Published As

Publication number Publication date
TWI299001B (en) 2008-07-21
US20030036553A1 (en) 2003-02-20
US20040204457A1 (en) 2004-10-14
EP1289527A2 (de) 2003-03-12
AU2001264842B2 (en) 2005-01-27
CN1436078A (zh) 2003-08-13
AU6484201A (en) 2001-12-03
MXPA02011511A (es) 2003-04-25
US7132433B2 (en) 2006-11-07
WO2001089498A2 (en) 2001-11-29
KR20030034078A (ko) 2003-05-01
JP2003535058A (ja) 2003-11-25
EP1289527B1 (de) 2008-03-26
NZ522659A (en) 2004-06-25
NO20025630L (no) 2003-01-24
IL152908A0 (en) 2003-06-24
DE60133385D1 (de) 2008-05-08
US20020099076A1 (en) 2002-07-25
AR029666A1 (es) 2003-07-10
PT1289527E (pt) 2008-05-13
CA2410554A1 (en) 2001-11-29
KR100784655B1 (ko) 2007-12-12
DK1289527T3 (da) 2008-07-14
PL359176A1 (en) 2004-08-23
DE60133385T2 (de) 2009-04-23
ES2300333T3 (es) 2008-06-16
CA2410554C (en) 2009-02-03
BR0111102A (pt) 2003-03-11
WO2001089498A3 (en) 2002-05-10
NO20025630D0 (no) 2002-11-22

Similar Documents

Publication Publication Date Title
ATE250605T1 (de) Piperidin verbindung zur behandlung von psoriasis
DE60132777D1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
NO20014047L (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE297917T1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1289527

Country of ref document: EP

REN Ceased due to non-payment of the annual fee